Viralytics Looks To Combos To Ride Immuno-Oncology Wave
This article was originally published in PharmAsia News
Executive Summary
Australian oncology venture Viralytics is on something of a roll, announcing additional positive Phase II data for its lead drug Cavatak and progress with new plans to assess the oncolytic virus in combination with immune checkpoint inhibitors following promising early results.